It can be overcome by the anti-IL-4Rα antibody dupilumab, which disrupts IL-13/IL-4 signaling, highlighting the central role of IL-13/IL-4 signaling dysregulation in AD pathogenesis [263]. Here, IL13 is linked to Alzheimer disease.